Status:
COMPLETED
A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This Phase II study is open to patients with metastatic colorectal cancer who have tried but failed chemotherapy regimens containing oxaliplatin and irinotecan. Patients must not have received anti-EG...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with metastatic colorectal cancer who have failed both oxaliplatin- and irinotecan-based regimens
- Tumour sample available for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation testing and other biomarker analyses.
- Exclusion criteria:
- Prior treatment with Epidermal Growth Factor Receptor (EGFR) targeting small molecules or antibodies.
- Biological treatment (including Bevacizumab or any other antiangiogenic agents) during the trial is not allowed.
- Known pre-existing interstitial lung disease.
- Planned major surgical procedures during the trial period.
Exclusion
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT01152437
Start Date
June 1 2010
Last Update
June 26 2014
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
1200.74.44001 Boehringer Ingelheim Investigational Site
Bournemouth, United Kingdom
2
1200.74.44005 Boehringer Ingelheim Investigational Site
Bristol, United Kingdom
3
1200.74.44006 Boehringer Ingelheim Investigational Site
Cambridge, United Kingdom
4
1200.74.44003 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom